September is 
COVID-19 Pandemic Update:
At Vivoryon, our primary concern remains adhering to government regulations to ensure our employees and their families are safe as we continue moving operations forward to the best of our abilities.
As the situation continues to evolve, we will provide updates should the pandemic have any direct effects on our business operations or clinical trials.
Our Story
Vivoryon Therapeutics has an experienced discovery and development team with a strong track record in delivering therapies to patients. We have product candidates in both clinical and preclinical development and are focusing on age-related diseases with unmet medical need.
We are relentless and focused on putting patients at the center of everything we do and strive to develop life-changing medicines.
Our Strategy
Identify and rapidly develop product candidates with clear biology, validated mechanisms and the potential to deliver life-changing improvement to patients suffering from age-related diseases.
first-in-class clinical phase 2 molecule in Alzheimer’s disease
clinical phase 1/2 ready first-in-class molecule for cancer immune checkpoint inhibition
patent families around QPCT and QPCTL inhibitors
track-record of bringing drugs from research into clinic
in vivo characterized small molecule inhibitors for cancer immune checkpoint inhibition
family of diabetes blockbuster drugs based on our research